Sick Economics

Searching For Healthy Profits In The Stock Market

BET ON THE ADULTS IN THE ROOM

the big five healthcare stocks

If we imagine corporations as if they were people on a natural life cycle, then most of the biotechs named above would be like toddlers or even infants; filled with vast potential, but still unproven. Another way to go is to invest in, “the Big Five.” These are the originators of biotechnology who have beaten long odds and matured into “teenagers” (the Big Five are typically 10-20 years old as of the writing of this book…). Much like human teenagers you may know, they could very much resemble adults, but they still have a lot of growing to do. That restless and painful process of growth is what could generate outsized returns for years to come. In 2015, these “Big Five” biotechnology stocks generated 83% of the profits for the entire NASDAQ Biotechnology Index:

-Gilead ($17,000,000,000 profit)
-Amgen ($6,000,000,000 profit)
-Shire ($4,000,000,000 profit)
-Celgene ($3,000,000 profit)
-Mylan (1,800,000,000 profit)

These companies have also generated world beating returns over the last ten years

-Gilead (369%)
-Amgen (132%)
-Shire (181%)
-Celgene (331%)
-Mylan (73%)

Along the way to becoming established corporate forces with solid, sustainable profits and noteworthy long term stock market returns, these companies have relentlessly pursued technological advances and cures (cures, not just treatments) that have saved thousands of lives. Although they have taken on many of the characteristics of the sluggish Big Pharma beasts that they were born to rival, they may still benefit from a scrappy “outsider” culture, just the way that now dominant Nasdaq royalty such as Google and Amazon still encourage their executives to dream big and push boundaries.

Now that the “big five” have thousands of employees and deep pockets, it might be reasonable to ask, “is all the growth behind them?” Well, consider these metrics. Pfizer, the granddaddy of all Big Pharmas, has current market capitalization of $198 Billion. (this means that if you were to attempt to buy all of Pfizer corporation for your own personal ownership, you would need to somehow come up with more than $198,000,000,000.) Gilead, the most profitable of the “Big Five” biotechs, only has a market capitalization of $89 Billion. So, if Gilead is well managed and has some luck, it’s not impossible to imagine this “teenager” doubling or tripling over the next 10 years to rival Pfizer.

Subscribe To Our Newsletter And Get Your Free E-Book

sick economics

You understand that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the bloggers, information providers, app providers, or their affiliates are advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the Site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors.

The Site is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Sick Economics or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.

ACCEPT